There currently exist few effective treatment options for patients with Advanced Gastro-Oesophageal Cancer (AGOC) that has returned after surgery, or where it is incurable (metastatic) at diagnosis. Chemotherapy can be effective at first, but once the cancer has become resistant to it, the options for treatment are limited. A second course of a different chemotherapy (docetaxel or irinotecan) can prolong survival, but not all patients are fit to receive this treatment. For those who do receive a second course, their cancer will eventually become resistant (or “refractory”) to these drugs. In both of these situations, there are currently no accepted treatment options that have been shown to be both effective against the cancer and tolerable for patients. Better treatment options are urgently needed.
Regorafenib (BAY 73-4506) is a ‘multi-targeted therapy’ targeting a number of different signals in the cancer cell that cause it to grow and produce blood vessels. In other cancers, such as colon cancer and GIST, regorafenib has been proven to be of benefit when other drugs have ceased to work. The AGITG Phase II trial — INTEGRATE, demonstrated efficacy with the use of regorafenib in AGOC, and could potentially become a new standard of care after other therapeutic agents have stopped working. INTEGRATE II is being undertaken to confirm the findings of the INTEGRATE Phase II trial in a larger population.
If the study is positive it will provide evidence for regorafenib as a new standard of care after other treatments no longer benefit patients with gastric cancer.
INTEGRATE II was presented at the American Society of Clinical Oncology (ASCO) in Chicago in early June in the progress session. Dr Katrin Sjoquist, INTEGRATE II Principal Investigator at St George Hospital (pictured above) commented:
“I was pleased to present the INTEGRATE II poster on behalf of the team at ASCO this year. The Trials In Progress session was a great opportunity to highlight this trial and we received overwhelmingly positive feedback”